---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018576"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:42:19.897798+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix Q1 rev $5.9M, net income $0.8M; PUR1900 study wind down, cash runway into Q1 2026

## Summary
- Revenue $5.9M (up $4.4M YoY) due to Cipla contract modification catch-up.
- Net income $0.8M vs net loss $4.4M in prior year.
- Cash $16.3M; expects cash runway into Q1 2026.
- PUR1900 Phase 2b stopped (no safety concern); Pulmatrix bears no further dev cost, gets 2% royalty on ex-US sales.
- PUR3100 Phase 2-ready; seeking partnership for Phase 2 study.

## SEC filing metadata
- accession: 0001493152-24-018576
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315224018576/0001493152-24-018576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315224018576/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018576
- JSON: https://secwatch.observer/filing/0001493152-24-018576.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018576.txt

## Key facts
- Earnings Releases
  Pulmatrix, Inc. reported three months ended March 31, 2024 results: revenue $5.9 million, net income $0.8 million.
  - Period: three months ended March 31, 2024
  - Revenue: $5.9 million
  - Net income: $0.8 million
  - Result: reported results
  source text: outside the United States. Within the United States, Pulmatrix and Cipla will seek to monetize PUR1900. First Quarter 2024 Financial Results Revenues increased $4.4 million to $5.9 million for the three months ended March 31, 2024, compared to $1.5 million for the three months ended March 31, 2023. The increase is primarily related to a contract modification of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574235/000149315224018576/0001493152-24-018576-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.